Related Experiment Videos
Long-term effects of simvastatin in familial dysbetalipoproteinaemia
P M Stuyt1, M J Mol, A F Stalenhoef
1Department of Medicine, University Hospital Nijmegen, The Netherlands.
Insights
Simvastatin effectively lowers cholesterol and triglycerides in familial dysbetalipoproteinaemia patients over 66 weeks. Both once and twice-daily dosing showed similar results with good tolerability.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Familial dysbetalipoproteinaemia, also known as type III hyperlipoproteinaemia, is a rare genetic disorder.
- It is characterized by elevated levels of cholesterol and triglycerides due to abnormal lipoprotein metabolism.
Purpose of the Study:
- To evaluate the long-term efficacy and tolerability of simvastatin in patients with familial dysbetalipoproteinaemia.
- To compare the effects of once-daily versus twice-daily simvastatin dosing.
Main Methods:
- A 66-week study involving 12 patients with familial dysbetalipoproteinaemia.
- Patients received simvastatin 40 mg daily, administered either once or twice per day.
- Serum lipid levels, including cholesterol and triglycerides, were monitored throughout the study.
Main Results:
- Simvastatin demonstrated a persistent hypolipidaemic effect, reducing serum cholesterol by 36-51% and triglycerides by 32-55%.
- The lipid reduction was attributed to decreased very-low-density lipoprotein (VLDL)-cholesterol and low-density lipoprotein (LDL)-cholesterol levels.
- No significant difference in efficacy was observed between once-daily and twice-daily dosing regimens.
- Simvastatin was well tolerated, with no serious adverse events reported.
Conclusions:
- Simvastatin is a useful and well-tolerated therapeutic option for managing familial dysbetalipoproteinaemia.
- Long-term treatment with simvastatin can significantly improve lipid profiles in affected individuals.
Abstract:
The long-term effects (66 weeks) of simvastatin (40 mg in one or two doses per day), an inhibitor of HMG CoA-reductase, were evaluated in 12 patients with familial dysbetalipoproteinaemia (type III hyperlipoproteinaemia). Simvastatin had a persistent hypolipidaemic effect; the mean reduction in serum cholesterol was 36-51%, and the mean reduction in serum triglycerides was 32-55%. The decrease in serum lipids was caused by a decline in VLDL-cholesterol and LDL-cholesterol levels; the mean ratio between VLDL-cholesterol and serum triglycerides decreased significantly from 1.06 to 0.73. There was no significant difference between the once-a-day and twice-a-day regimens. Simvastatin was well tolerated; no serious side-effects were observed. These data demonstrate the usefulness of simvastatin in the therapy of familial dysbetalipoproteinaemia.